Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPrognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy
Cancer, 06/26/09
Park I et al. - In a study to investigate prognostic factors in pts with advanced biliary tract adenocarcinoma (BTA) receiving first-line palliative chemotherapy, it appears that 5 prognostic factors in pts with advanced BTA were identified. The predictive model based on prognostic index (PI) appears to be promising and may be used for management of individual pts and to guide design of future clinical trials.
Methods- Data from 213 pts with advanced BTA who were in prospective phase 2 or retrospective studies from September 2000 through October 2007 were used.
- With a median follow-up duration of 29.7 mos, median overall survival (OS) was 7.3 mos.
- Cox proportional hazards model indicated that metastatic disease, intrahepatic cholangiocellular carcinoma, liver metastasis, ECOG performance status, and alkaline phosphatase level (IU/L) were statistically significant independent predictors of poor prognosis.
- Pts were classified into 3 risk groups based on PI, which was constructed using the regression coefficients of each variable.
- Median OS was 11.5 mos for the low-risk group (PI ≤1.5; n=67), 7.3 mos for the intermediate-risk group (PI >1.5 but ≤2.2; n=75), and 3.6 mos for the high-risk group (PI >2.2; n=70).
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery
Cancer Chemotherapy and Pharmacology, 12/17/09
Decreased expression of KLF6 and its significance in gastric carcinoma
Medical Oncology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor